NEW YORK (GenomeWeb News) – Becton, Dickinson and Company today reported a 14.5 percent increase in third-quarter revenues accompanied by a 21.4 percent increase in net income.
For the quarter ended June 30, BD’s revenues rose to $1.9 billion from $1.6 billion in the comparable period of 2007. The company said that 7 percent of that growth was due to the favorable impact of foreign currency translation.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.